Astra Tech's, pioneering work in the field of urology was recognised the 2006's conventional PVC, non-hydrophilic products of the year award, from international business consultants Frost and Sullivan, on July 12.
The Swedish medical devices company, a subsidiary of Astra Zeneca is a world leader in the fast-growing field of intermittent catheterisation and its contribution to improved treatment standards for patients was key to winning this prestigious international accolade.
By making intermittent self-catheterisation a convenient, clean and safe process through its innovative LoFric hydrophilic product, Astra Tech has "Improved the quality of life of users by reducing the trauma and complications that were once associated with this procedure," says the Award citation.
The world's first hydrophilic catheter, was introduced by Astra Tech in 1983, giving users the freedom of self-administered intermittent treatment, and since then a wide range of LoFric catheters has been developed, all using Urotonic Surface Technology to reduce friction and minimise the risk of inflammation.
"Product innovation, technology excellence, extensive documentation, on-going long-term studies and significant support and training have all resulted in a product that customers perceive as to being synonymous with reliability, safety and convenience," adds the citation.
In conferring its 2006 TIL's award, Frost and Sullivan evaluated Astra Tech's performance across all stages of the technology life cycle, including incubation, adaptation, take-up and maturity, to ensure a continuous flow of improvements.
Prof. Gerard Amarenco of Rothschild University Hospital, Paris, a leading expert in the treatment of urinary dysfunction, has been prescribing LoFric catheters for 15 years. He has carried out a pan-European study among 425 disabled patients suffering from severe spinal and neurological conditions that make intermittent self-catheterisation a necessity. On entry into the study, a variety of different catheters were being used, including conventional PVC, non-hydrophilic products.
"Astra Tech were first to develop the hydrophilic catheter and there's no doubt their product is still one of the best on the market," says Prof. Amarenco. "Over the years, the company has continued to improve and refine the technology and their work has made a valuable contribution to improving the quality of life of patients. This award is well deserved."
"We are very proud and pleased to win this award from such a respected organisation as Frost and Sullivan. It recognises the effective research and development work of our company which benefits both patients and professionals in the healthcare sector." Said Astra Tech President and CEO Peter Selley ,"Our policy is to continue improving the existing LoFric product line and we plan to introduce further developments in the future."
Astra Tech aims, to improve treatment results, facilitate procedures, reduce health care costs and enhance the quality of life for patients.